These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 24263462

  • 1. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability.
    Pastores GM, Rosenbloom B, Weinreb N, Goker-Alpan O, Grabowski G, Cohn GM, Zahrieh D.
    Genet Med; 2014 May; 16(5):359-66. PubMed ID: 24263462
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, Giraldo P, Kisinovsky I, Bavdekar A, Ben Dridi MF, Gupta N, Kishnani PS, Sureshkumar EK, Wang N, Crombez E, Bhirangi K, Mehta A.
    Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D, Mehta A, Hughes DA, Giraldo P, Charrow J, Smith L, Shankar SP, Hangartner TN, Kunes Y, Wang N, Crombez E, Zimran A.
    Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Safety of use of velaglucerase in 2 patients with type 1 Gaucher's disease].
    Latre P, Giraldo P.
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():39-42. PubMed ID: 22230124
    [Abstract] [Full Text] [Related]

  • 14. Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan.
    Sagara R, Ishigaki M, Otsuka M, Murayama K, Ida H, Fernandez J.
    Orphanet J Rare Dis; 2021 Dec 04; 16(1):502. PubMed ID: 34863216
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, Amato DJ, Mengel E, Tan ES, Chertkoff R, Brill-Almon E, Zimran A.
    Blood Cells Mol Dis; 2014 Dec 04; 53(4):253-60. PubMed ID: 24950666
    [Abstract] [Full Text] [Related]

  • 17. Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease.
    Elstein D, Burrow TA, Charrow J, Giraldo P, Mehta A, Pastores GM, Lee HM, Mellgard B, Zimran A.
    Mol Genet Metab; 2017 Dec 04; 120(1-2):111-115. PubMed ID: 27614581
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
    Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Cooper PA, Varughese S, Giraldo P, Petakov M, Tan ES, Chertkoff R.
    Blood Cells Mol Dis; 2018 Feb 04; 68():163-172. PubMed ID: 27839981
    [Abstract] [Full Text] [Related]

  • 20. 13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease.
    Elstein D, Abrahamov A, Oz A, Arbel N, Baris H, Zimran A.
    Blood Cells Mol Dis; 2015 Dec 04; 55(4):415-8. PubMed ID: 26460268
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.